{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:24:04Z","timestamp":1793931844911,"version":"4.8.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite increasing availability of therapies, patients with Sezary syndrome (SS) commonly endure multi-line treatment journeys, mostly with partial responses of short duration. Measuring clinical benefit is challenging; time-to-next-treatment (TTNT) provides a robust, objective measurement of efficacy. This international observational study examines patterns of clinical care and therapeutic benefit as measured by TTNT. TTNT was calculated for monotherapies and combination therapies, with consideration to treatment line. 178 patients with SS (73% de novo, 27% secondary) were included, receiving 721 lines of systemic therapy, with median follow-up of 56.9\u00a0months. Across all lines, 58 different therapeutic regimens were prescribed (54 were systemic therapies) and classified into 17 treatment groups. The most common first-line treatments were extracorporeal photopheresis (ECP)\u2013containing combination therapy (20%) and retinoid monotherapy (19%). Median TTNT for all first-line therapies was short (5.4\u00a0months). First-line, combination therapies had longer median TTNT than monotherapies, 10.0 vs 5.0\u00a0months (P\u00a0= .004), respectively. Later delivery of combination therapies was associated with shorter clinical benefit, with median TTNT reduced to 6.2 and 2.2\u00a0months for mid-line (2nd-4th line) and late-line (\u22655th line), respectively (P\u00a0&amp;lt; .001). First-line ECP-containing treatments were associated with longer median TTNT than non-ECP\u2013containing treatments, 9.0 vs 4.9\u00a0months (P\u00a0= .007). For both ECP-monotherapy and ECP\u2013containing combination therapy, significant reductions in TTNT were seen in later lines. These data suggest therapeutic benefit from first-line delivery of combination therapy for SS and favor early inclusion of ECP in the treatment algorithm for those who can access it.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023011041","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T22:44:40Z","timestamp":1693435480000},"page":"6639-6647","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-8723","authenticated-orcid":false,"given":"Belinda A.","family":"Campbell","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia"},{"name":"2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia"},{"name":"3Department of Clinical Pathology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7197","authenticated-orcid":false,"given":"Gabor","family":"Dobos","sequence":"additional","affiliation":[{"name":"4Department of Dermatology, H\u00f4pital Saint Louis, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"5Department of Dermatology and Allergy, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Haider","sequence":"additional","affiliation":[{"name":"6Department of Dermatology, Queen Elizabeth Hospital, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia"},{"name":"8Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-5192","authenticated-orcid":false,"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"4Department of Dermatology, H\u00f4pital Saint Louis, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity","family":"Evison","sequence":"additional","affiliation":[{"name":"7Health Data Science Team, Research Development and Innovation, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-9876","authenticated-orcid":false,"given":"Carrie","family":"van der Weyden","sequence":"additional","affiliation":[{"name":"2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia"},{"name":"8Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"McCormack","sequence":"additional","affiliation":[{"name":"9Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia"},{"name":"11Department of Surgery, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ram-Wolff","sequence":"additional","affiliation":[{"name":"4Department of Dermatology, H\u00f4pital Saint Louis, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Miladi","sequence":"additional","affiliation":[{"name":"4Department of Dermatology, H\u00f4pital Saint Louis, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8011-4408","authenticated-orcid":false,"given":"Julia J","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"10Department of Dermatology, University Hospital Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"issue":"3","key":"2023111415203457100_bib1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/bjd.18089","article-title":"Characteristics associated with significantly worse quality of life in mycosis fungoides\/S\u00e9zary syndrome from the prospective cutaneous lymphoma international prognostic index (PROCLIPI) study","volume":"182","author":"Molloy","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"2023111415203457100_bib2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association Of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"issue":"Suppl 4","key":"2023111415203457100_bib3","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"2023111415203457100_bib4","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/ajd.13467","article-title":"Mycosis fungoides and S\u00e9zary syndrome: Australian clinical practice statement","volume":"62","author":"Bhabha","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"10","key":"2023111415203457100_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.annder.2010.06.021","article-title":"[Management of cutaneous T-cell lymphomas: recommendations of the French Cutaneous Lymphoma Group]","volume":"137","author":"Beylot-Barry","year":"2010","journal-title":"Ann Dermatol Venereol"},{"key":"2023111415203457100_bib6","author":"Network NCC","year":"2022"},{"key":"2023111415203457100_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4","key":"2023111415203457100_bib8","first-page":"537","article-title":"S2k-guidelines - cutaneous lymphomas (ICD10 C82 - C86): update 2021","volume":"20","author":"Dippel","year":"2022","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"1","key":"2023111415203457100_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/hematology.2021000263","article-title":"What factors guide treatment selection in mycosis fungoides and Sezary syndrome?","volume":"2021","author":"Kim","year":"2021\u00a0\u00a010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2023111415203457100_bib10","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicentre retrospective follow-up study from the cutaneous lymphoma international consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"},{"issue":"20","key":"2023111415203457100_bib11","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.3390\/ijms222011079","article-title":"Clinical guidelines and new molecular targets for cutaneous lymphomas","volume":"22","author":"Sugaya","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2023111415203457100_bib12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"2023111415203457100_bib13","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jdv.17523","article-title":"Efficacy and safety of mogamulizumab by patient baseline blood tumor burden: a post hoc analysis of the MAVORIC trial","volume":"35","author":"Cowan","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"2023111415203457100_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2023111415203457100_bib15","doi-asserted-by":"crossref","first-page":"E491","DOI":"10.1002\/ajh.24564","article-title":"A\u00a0retrospective comparative outcome analysis following systemic therapy in mycosis fungoides and Sezary syndrome","volume":"91","author":"Hanel","year":"2016","journal-title":"Am J Hematol"},{"issue":"16","key":"2023111415203457100_bib16","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.2019000765","article-title":"Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with S\u00e9zary syndrome","volume":"134","author":"Gao","year":"2019","journal-title":"Blood"},{"key":"2023111415203457100_bib17","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers11111758","article-title":"Lack of durable remission with conventional-dose total skin electron therapy for the management of Sezary syndrome and multiply relapsed mycosis fungoides","volume":"11","author":"Campbell","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2023111415203457100_bib18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjd.18522","article-title":"A\u00a0comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"182","author":"Papps","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023111415203457100_bib19","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(21)00678-X","article-title":"Qol-O-02 - Time-to-next-treatment and time-to-next-systemic treatment in patients included in the PROCLIPI registry","volume":"156","author":"Quaglino","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"2023111415203457100_bib20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjd.20588","article-title":"Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and S\u00e9zary syndrome with variable CD30 positivity","volume":"185","author":"Papadavid","year":"2021","journal-title":"Br J Dermatol"},{"issue":"20","key":"2023111415203457100_bib21","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1002\/cam4.4237","article-title":"Alitretinoin in the treatment of cutaneous T-cell lymphoma","volume":"10","author":"Kaemmerer","year":"2021","journal-title":"Cancer Med"},{"issue":"9","key":"2023111415203457100_bib22","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1080\/10428194.2022.2067999","article-title":"African American and Caucasian patients with S\u00e9zary syndrome have no differences in outcomes at an ethnically diverse urban medical centre","volume":"63","author":"Martini","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2023111415203457100_bib23","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/s41409-022-01787-3","article-title":"Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides","volume":"57","author":"Elliott","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2023111415203457100_bib24","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/bjd.21772","article-title":"Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin","volume":"187","author":"Roccuzzo","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023111415203457100_bib25","doi-asserted-by":"crossref","first-page":"884091","DOI":"10.3389\/fonc.2022.884091","article-title":"Retrospective analysis of 118 patients with cutaneous T-cell lymphomas: a single-centre experience","volume":"12","author":"Polg\u00e1rov\u00e1","year":"2022  7","journal-title":"Front Oncol"},{"issue":"23","key":"2023111415203457100_bib26","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"2023111415203457100_bib27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2023111415203457100_bib28","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020  17","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2023111415203457100_bib29","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society For Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"2023111415203457100_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and S\u00e9zary syndrome using flow cytometry: recommendations from the EORTC Cutaneous Lymphoma Task Force","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer"},{"issue":"9","key":"2023111415203457100_bib31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis fungoides and S\u00e9zary syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am J Hematol"},{"issue":"20","key":"2023111415203457100_bib32","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"14","author":"Prince","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2023111415203457100_bib33","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"issue":"6","key":"2023111415203457100_bib34","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jval.2021.11.1364","article-title":"Cost-effectiveness of extracorporeal photopheresis for the treatment of patients with erythrodermic (stage T4, M0) cutaneous T-cell lymphoma in the Australian setting","volume":"25","author":"Peacock","year":"2022","journal-title":"Value Health"},{"issue":"6","key":"2023111415203457100_bib35","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41409-020-01150-4","article-title":"Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and S\u00e9zary syndrome: never-late, never-never?","volume":"56","author":"Prince","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2023111415203457100_bib36","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"issue":"18","key":"2023111415203457100_bib37","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1182\/bloodadvances.2020001627","article-title":"Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma","volume":"4","author":"Weng","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2023111415203457100_bib38","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S\u00e9zary syndrome. an updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"56","author":"Domingo-Domenech","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2023111415203457100_bib39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"2023111415203457100_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.19252","article-title":"Treatment of early-stage mycosis fungoides: results from the prospective cutaneous lymphoma international prognostic index (PROCLIPI) study\u2217","volume":"184","author":"Quaglino","year":"2021","journal-title":"Br J Dermatol"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2023012318","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6639\/2089062\/blooda_adv-2023-011041-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6639\/2089062\/blooda_adv-2023-011041-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:21:45Z","timestamp":1699957305000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6639\/497698\/International-study-of-treatment-efficacy-in-SS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":40,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011041","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2023012318","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]}}}